Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

1. A range of anti-epilepsy drugs are effective as first-line treatment

A range of anti-epilepsy drugs are effective as first-line treatment Signal - A range of anti-epilepsy drugs are effective as first-line treatment Dissemination Centre Discover Portal NIHR DC Discover A range of anti-epilepsy drugs are effective as first-line treatment Published on 12 September 2017 Lamotrigine and levetiracetam are emerging as first-line treatments for epilepsy, which people may be more likely to keep taking than carbamazepine. Reducing the risk of adverse events and treatment (...) withdrawal is important when selecting an anti-epilepsy drug as it usually will need to be taken long-term. This study reviewed evidence on anti-epilepsy drugs in adults and children. The drugs were compared directly or indirectly with each other. The main outcome of interest was time to withdrawal from treatment, which indicates effectiveness and tolerability. The findings support NICE recommendations to use carbamazepine or lamotrigine as first-line therapies for epilepsy with partial seizures

2019 NIHR Dissemination Centre

2. Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase

Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Dissemination Centre Discover Portal NIHR DC Discover Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Published on 26 June 2018 doi: In people with some types of severe, drug-resistant epilepsy, adding cannabidiol (...) to their treatment may reduce seizure frequency and improve quality of life compared with a placebo. The likelihood of being free from seizures for more than a year was still low, about 8%. However, serious adverse effects were 12% more likely with cannabidiol. These findings come from a systematic review, which included six trials in 555 patients. Most were children and adolescents with rare forms of epilepsy, and findings may not apply to other forms of the condition. The included trials were poorly reported

2019 NIHR Dissemination Centre

3. Topiramate for juvenile myoclonic epilepsy. (PubMed)

Topiramate for juvenile myoclonic epilepsy. BACKGROUND: Topiramate is a newer broad-spectrum antiepileptic drug (AED). Some studies have shown the benefits of topiramate in the treatment of juvenile myoclonic epilepsy (JME). However, there are no current systematic reviews to determine the efficacy and tolerability of topiramate in people with JME. This is an update of a Cochrane Review first published in 2015, and last updated in 2017. OBJECTIVES: To evaluate the efficacy and tolerability (...) of topiramate in the treatment of JME. SEARCH METHODS: For the latest update, on 10 July 2018 we searched the Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group's Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid 1946- ), and ClinicalTrials.gov. We also searched ongoing trials registers, reference lists and relevant conference proceedings, and contacted study authors and pharmaceutical companies. SELECTION CRITERIA: We

2019 Cochrane

4. Brivaracetam (Briviact) for use in the treatment of patients with refractory epilepsy

Brivaracetam (Briviact) for use in the treatment of patients with refractory epilepsy Brivaracetam (Briviact ® ). Reference number 3387. Page 1 of 3 AWMSG Secretariat Assessment Report – Limited submission Brivaracetam (Briviact ® ? ) 10 mg, 25 mg, 50 mg, 75 mg and 100 mg film-coated tablets; 10 mg/ml oral solution; 10 mg/ml solution for injection/infusion Company: UCB Pharma Ltd Licensed indication under consideration: As adjunctive therapy in the treatment of partial onset seizures (...) with or without secondary generalisation in children from 4 to = 15 years of age with epilepsy. Brivaracetam (Briviact ® ) should be restricted to use in the treatment of patients with refractory epilepsy, who remain uncontrolled with, or are intolerant to, other adjunctive anti-epileptic medicines. ? This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Date

2019 All Wales Medicines Strategy Group

5. Surgical outcomes for medically intractable epilepsy in low- and middle-income countries: a systematic review and meta-analysis

Surgical outcomes for medically intractable epilepsy in low- and middle-income countries: a systematic review and meta-analysis 30497170 2019 01 05 1933-0693 2018 Nov 01 Journal of neurosurgery J. Neurosurg. Surgical outcomes for medically intractable epilepsy in low- and middle-income countries: a systematic review and meta-analysis. 1-11 10.3171/2018.5.JNS18599 2018.5.JNS18599 OBJECTIVEThe aim of this study was to describe the current state of epilepsy surgery and establish estimates (...) of seizure outcomes following surgery for medically intractable epilepsy (MIE) in low- and middle-income countries (LMICs).METHODSThe MEDLINE and Embase databases were searched without publication date restriction. This search was supplemented by a manual screen of key epilepsy and neurosurgical journals (January 2005 to December 2016). Studies that reported outcomes for at least 10 patients of any age undergoing surgery for MIE in LMICs over a defined follow-up period were included. A meta-analysis

2019 EvidenceUpdates

6. A Prediction Model to Determine Childhood Epilepsy After 1 or More Paroxysmal Events

A Prediction Model to Determine Childhood Epilepsy After 1 or More Paroxysmal Events 30389715 2018 12 04 1098-4275 142 6 2018 Dec Pediatrics Pediatrics A Prediction Model to Determine Childhood Epilepsy After 1 or More Paroxysmal Events. e20180931 10.1542/peds.2018-0931 The clinical profile of children who had possible seizures is heterogeneous, and accuracy of diagnostic testing is limited. We aimed to develop and validate a prediction model that determines the risk of childhood epilepsy (...) by combining available information at first consultation. We retrospectively collected data of 451 children who visited our outpatient department for diagnostic workup related to 1 or more paroxysmal event(s). At least 1 year of follow-up was available for all children who were diagnosed with epilepsy or in whom diagnosis remained inconclusive. Clinical characteristics (sex, age of first seizure, event description, medical history) and EEG report were used as predictor variables for building a multivariate

2019 EvidenceUpdates

7. Treatment of epilepsy for people with Alzheimer's disease. (PubMed)

Treatment of epilepsy for people with Alzheimer's disease. BACKGROUND: Any type of seizure can be observed in Alzheimer's disease (AD). Antiepileptic drugs seem to prevent the recurrence of epileptic seizures in most people with AD. There are pharmacological and non-pharmacological treatments for epilepsy in people with AD. There are no current systematic reviews to evaluate the efficacy and tolerability of these treatments; this review aims to review those different modalities (...) . This is an updated version of the original Cochrane Review published in Issue 11, 2016. OBJECTIVES: To assess the efficacy and tolerability of pharmacological or non-pharmacological interventions for the treatment of epilepsy in people with AD (including sporadic AD and dominantly inherited AD). SEARCH METHODS: For the latest update, on 10 July 2018 we searched the Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group's Specialized Register and the Cochrane Central Register

2018 Cochrane

8. Nomograms to predict naming decline after temporal lobe surgery in adults with epilepsy

Nomograms to predict naming decline after temporal lobe surgery in adults with epilepsy 30404781 2018 12 04 1526-632X 91 23 2018 Dec 04 Neurology Neurology Nomograms to predict naming decline after temporal lobe surgery in adults with epilepsy. e2144-e2152 10.1212/WNL.0000000000006629 To develop and externally validate models to predict the probability of postoperative naming decline in adults following temporal lobe epilepsy surgery using easily accessible preoperative clinical predictors (...) . In this retrospective, prediction model development study, multivariable models were developed in a cohort of 719 patients who underwent temporal lobe epilepsy surgery at Cleveland Clinic and externally validated in a cohort of 138 patients who underwent temporal lobe surgery at one of 3 epilepsy surgery centers in the United States (Columbia University Medical Center, Emory University School of Medicine, University of Washington School of Medicine). The development cohort was 54% female with an average age

2018 EvidenceUpdates

9. Ketogenic diets for drug-resistant epilepsy. (PubMed)

Ketogenic diets for drug-resistant epilepsy. BACKGROUND: Ketogenic diets (KDs), being high in fat and low in carbohydrates, have been suggested to reduce seizure frequency in people with epilepsy. At present, such diets are mainly recommended for children who continue to have seizures despite treatment with antiepileptic drugs (AEDs) (drug-resistant epilepsy). Recently, there has been interest in less restrictive KDs, including the modified Atkins diet (MAD), and the use of these diets has (...) extended into adult practice. This is an update of a review first published in 2003 and last updated in 2016. OBJECTIVES: To assess the effects of KDs for drug-resistant epilepsy by reviewing the evidence from randomised controlled trials. SEARCH METHODS: For the latest update we searched the Cochrane Epilepsy Group's Specialized Register (11 April 2017), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 11 April 2017), MEDLINE (Ovid, 11

2018 Cochrane

10. Perampanel (epilepsy) - Benefit assessment according to §35a Social Code Book (SGB) V

Perampanel (epilepsy) - Benefit assessment according to §35a Social Code Book (SGB) V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Perampanel (Epilepsie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 26 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-61 Perampanel (epilepsy (...) ) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-61 Version 1.0 Perampanel (epilepsy) 26 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Perampanel (epilepsy) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 30 November 2017 Internal Commission No.: A17-61 Address

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. Subpial transection surgery for epilepsy. (PubMed)

Subpial transection surgery for epilepsy. BACKGROUND: Nearly 30% of patients with epilepsy continue to have seizures despite using several antiepileptic drugs (AEDs). Such patients are regarded as having refractory, or uncontrolled, epilepsy. While there is no universally accepted definition of uncontrolled, or medically refractory, epilepsy, for the purposes of this review we will consider seizures as drug resistant if they have failed to respond to a minimum of two AEDs. Specialists consider (...) that early surgical intervention may prevent seizures at a younger age, which in turn may improve the intellectual and social status of children. Many types of surgery are available for treating refractory epilepsy; one such procedure is known as subpial transection. OBJECTIVES: To assess the effects of subpial transection for focal-onset seizures and generalised tonic-clonic seizures in children and adults. SEARCH METHODS: For the latest update we searched the following databases on 7 August 2018

2018 Cochrane

12. Gabapentin add-on treatment for drug-resistant focal epilepsy. (PubMed)

Gabapentin add-on treatment for drug-resistant focal epilepsy. BACKGROUND: This is an updated version of the Cochrane Review previously published in 2013.Most people with epilepsy have a good prognosis and their seizures are well controlled by a single antiepileptic drug, but up to 30% develop drug-resistant epilepsy, especially those with focal seizures. In this review, we summarised the evidence from randomised controlled trials (RCTs) of gabapentin, when used as an add-on treatment for drug (...) -resistant focal epilepsy. OBJECTIVES: To evaluate the efficacy and tolerability of gabapentin when used as an add-on treatment for people with drug-resistant focal epilepsy. SEARCH METHODS: For the latest update, we searched the Cochrane Register of Studies (CRS Web, 20 March 2018), which includes the Cochrane Epilepsy Group's Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid, 1946 to 20 March 2018), ClinicalTrials.gov (20 March 2018) and the World

2018 Cochrane

13. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. (PubMed)

Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. BACKGROUND: This is an updated version of the Cochrane Review previously published in 2016. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70 (...) % of individuals with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.Worldwide, carbamazepine and phenobarbitone are commonly used broad-spectrum antiepileptic drugs, suitable for most epileptic seizure types. Carbamazepine is a current first-line treatment for focal onset seizures, and is used in the USA and Europe. Phenobarbitone is no longer considered a first-line treatment because

2018 Cochrane

14. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. (PubMed)

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. BACKGROUND: This is an updated version of the Cochrane Review previously published in 2013. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70% of individuals (...) with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.Worldwide, phenytoin is a commonly used antiepileptic drug. It is important to know how newer drugs, such as oxcarbazepine, compare with commonly used standard treatments. OBJECTIVES: To review the time to treatment failure, remission and first seizure with oxcarbazepine compared to phenytoin, when used as monotherapy in people

2018 Cochrane

15. Zonisamide add-on therapy for focal epilepsy. (PubMed)

Zonisamide add-on therapy for focal epilepsy. BACKGROUND: The majority of people with epilepsy have a good prognosis, and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop refractory epilepsy, especially those with focal seizures. In this review, we summarised the evidence from randomised controlled trials (RCT) of zonisamide, used as an add-on treatment for focal epilepsy uncontrolled by one or more concomitant antiepileptic drug (...) . This is an updated version of the Cochrane review previously published in 2013. OBJECTIVES: To evaluate the efficacy and tolerability of zonisamide, when used as an add-on treatment for people with focal epilepsy uncontrolled by one or more concomitant antiepileptic drugs. SEARCH METHODS: For this update, on 4 September 2017, we searched the Cochrane Epilepsy Group Specialised Register, Cochrane Register of Studies Online, MEDLINE Ovid, ClinicalTrials.gov, and the WHO International Clinical Trials Registry

2018 Cochrane

16. Vigabatrin (Kigabeq) - epilepsy in children between 1 month and 7 years of age

Vigabatrin (Kigabeq) - epilepsy in children between 1 month and 7 years of age Kigabeq | European Medicines Agency Search Search Menu Kigabeq vigabatrin Table of contents Authorised This medicine is authorised for use in the European Union. Overview Kigabeq is a medicine for treating epilepsy in children between 1 month and 7 years of age. It is used in the following ways: on its own to treat infantile spasms (West syndrome), a rare epilepsy disorder that starts at a very young age, usually (...) in the first few months of life; together with other medicines to treat partial epilepsy (seizures affecting one part of the brain), including when the seizures spread to other parts of the brain and become more generalised. Kigabeq is only used in partial epilepsy when patients have already tried all other appropriate treatments or cannot use them because of side effects. Kigabeq contains the vigabatrin and is a ‘ ’. This means that it is similar to a ‘reference medicine’ containing the same , but Kigabeq

2018 European Medicines Agency - EPARs

17. Validation of a Swahili version of the World Health Organization 5-item well-being index among adults living with HIV and epilepsy in rural coastal Kenya (PubMed)

Validation of a Swahili version of the World Health Organization 5-item well-being index among adults living with HIV and epilepsy in rural coastal Kenya 30214943 2018 11 14 2397-0642 3 2018 Global health research and policy Glob Health Res Policy Validation of a Swahili version of the World Health Organization 5-item well-being index among adults living with HIV and epilepsy in rural coastal Kenya. 26 10.1186/s41256-018-0081-z The purpose of this study was to evaluate the psychometric (...) properties of the World Health Organization's five item well-being index (WHO-5) when administered to adults living with HIV or epilepsy in a rural setting at the coast of Kenya. A case control study design was conducted among 230 adults aged 18-50 years, who comprised 147 cases (63 living with epilepsy and 84 living with HIV) and 83 healthy controls. The participants were administered to a face-to-face interview during which they completed the Swahili version of WHO-5 well-being index, the Major

Full Text available with Trip Pro

2018 Global health research and policy

18. Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review. (PubMed)

Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review. BACKGROUND: Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment up to 70% of individuals with active epilepsy have the potential to become seizure-free, and to go into long-term remission shortly after starting drug therapy with a single antiepileptic drug (...) , and updated in 2013 and 2016. OBJECTIVES: To review the time to treatment failure, remission and first seizure of sodium valproate compared to phenytoin when used as monotherapy in people with focal onset seizures or generalised tonic-clonic seizures (with or without other generalised seizure types). SEARCH METHODS: We searched the Cochrane Epilepsy Group's Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, ClinicalTrials.gov and the World Health Organization (WHO

2018 Cochrane

19. Epilepsy

Epilepsy Top results for epilepsy - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for epilepsy The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

2018 Trip Latest and Greatest

20. Systematic review and network meta-analysis of resective surgery for mesial temporal lobe epilepsy

Systematic review and network meta-analysis of resective surgery for mesial temporal lobe epilepsy 29769251 2018 05 17 1468-330X 2018 May 16 Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatry Systematic review and network meta-analysis of resective surgery for mesial temporal lobe epilepsy. jnnp-2017-317783 10.1136/jnnp-2017-317783 To evaluate the effectiveness of anterior temporal lobectomy (ATL) versus selective amygdalohippocampectomy (SAH) on seizure-free (...) outcome in patients with temporal lobe epilepsy, using both direct and indirect evidence from the literature. MEDLINE, Embase and Cochrane databases were searched for original research articles and systematic reviews comparing ATL versus SAH, and ATL or SAH versus medical management (MM). The outcome was seizure freedom at 12 months of follow-up or longer. Direct pairwise meta-analyses were conducted, followed by a random-effect Bayesian network meta-analysis (NMA) combining direct and indirect

2018 EvidenceUpdates